Deals
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push
- Deal would add specialist in blood, immune conditions
- Alexion holders would keep 15% ownership in combined company
This article is for subscribers only.
Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.
AstraZeneca Plc agreed to buy Alexion Pharmaceuticals Inc. for $39 billion in cash and shares, adding a specialist in the treatment of rare diseases and immunology to its portfolio of medications for cancer and other illnesses.